Based on comorbidities, researchers can use artificial intelligence to predict which COVID-19 symptoms a patient will develop.
Georgia Institute of Technology and Emory University researchers created a new artificial intelligence-based tool to assist clinicians in predicting which symptoms COVID-19 patients will experience based on comorbidities. Additionally, the AI tool can suggest specific FDA-approved drugs for treatment.
The new tool is called MOATAI-VIR (Mode Of Action proteins & Targeted therapeutic discovery driven by Artificial Intelligence for VIRuses.) According to researchers, the artificial intelligence tool predicts 24 out of 26 major clinical manifestations of COVID-19 and the underlying disease-protein-pathway relationships.
The clinical manifestations include a range of side effects such as acute respiratory distress, blood clotting issues, cytokine storms, low blood oxygen levels, low white blood cell counts, and marrow failure. Other more common symptoms, including loss of smell or taste and “brain fog,” were also examined.